賽洛唑啉

賽洛唑啉
臨床資料
讀音	/ˌzaɪloʊˌmɛtəˈzoʊliːn/; ZY-lo-MET-ə-ZOH-leen
商品名（英語：Drug nomenclature）	Otrivin, Otrivine, others
AHFS/Drugs.com	Monograph
MedlinePlus	a608026
核准狀況	美 DailyMed: Xylometazoline;
懷孕分級	C;
依賴性	Moderate
給藥途徑	intranasal (spray or drops)
藥物類別（英語：Drug class）	α1 and α2 adrenergic receptor agonist
ATC碼	R01AA07 (WHO) S01GA03;
法律規範狀態
法律規範	OTC;
藥物動力學數據
生物半衰期	>10 seconds
排泄途徑	Urinary
識別資訊
	IUPAC命名法 2-[(4-tert-butyl-2,6-dimethylphenyl)methyl]-; 4,5-dihydro-1H-imidazole; ;
CAS號	526-36-3
PubChem CID	5709;
IUPHAR/BPS	517;
DrugBank	DB06694 ;
ChemSpider	5507 ;
UNII	WPY40FTH8K;
KEGG	D08684 ;
ChEMBL	ChEMBL312448 ;
CompTox Dashboard（英語：CompTox Chemicals Dashboard） (EPA)	DTXSID8046957 ;
ECHA InfoCard	100.007.629
化學資訊
化學式	C16H24N2
摩爾質量	244.38 g·mol−1
3D模型（JSmol（英語：JSmol））	交互式圖像;
	SMILES N\1=C(\NCC/1)Cc2c(cc(cc2C)C(C)(C)C)C;
	InChI InChI=1S/C16H24N2/c1-11-8-13(16(3,4)5)9-12(2)14(11)10-15-17-6-7-18-15/h8-9H,6-7,10H2,1-5H3,(H,17,18) ; Key:HUCJFAOMUPXHDK-UHFFFAOYSA-N ;

賽洛唑啉（英文：Xylometazoline，也拼作xylomethazoline），是一種用於減輕鼻塞、過敏性鼻炎和鼻竇炎症狀的藥物。^[1] 不建議使用超過七天。^[2]同樣，不建議三個月以下的嬰兒使用，有的說法甚至建議不要在6歲以下兒童使用。^[2]^[3] 這種藥物是直接通過鼻子作為噴霧或滴劑使用的。^[2]

副作用包括失眠、鼻子刺激、噁心、鼻出血（3%）、月經疼痛（10%）和頭痛（3%）。^[4]^[1]^[2] 長期使用（>10天）不推薦，因為停用後可能會出現藥物性鼻炎。^[4]^[5]不建議在懷孕期間使用。^[1]賽洛唑啉屬於減充血劑和α腎上腺素受體激動劑這兩類藥物。^[5]^[6]

參考資料

^ ^1.0 ^1.1 ^1.2 Otrivine Adult Measured Dose Sinusitis Spray - Summary of Product Characteristics (SPC) - (eMC). www.medicines.org.uk. 13 April 2016 [28 December 2016]. （原始內容存檔於29 December 2016）.
^ ^2.0 ^2.1 ^2.2 ^2.3 British national formulary : BNF 69 69. British Medical Association. 2015: 786. ISBN 9780857111562.
^ World Health Organization. World Health Organization model list of essential medicines: 21st list 2019. Geneva: World Health Organization. 2019. hdl:10665/325771 . WHO/MVP/EMP/IAU/2019.06. License: CC BY-NC-SA 3.0 IGO.
^ ^4.0 ^4.1 Eccles R, Martensson K, Chen SC. Effects of intranasal xylometazoline, alone or in combination with ipratropium, in patients with common cold. Current Medical Research and Opinion. April 2010, 26 (4): 889–899. PMID 20151787. S2CID 34728458. doi:10.1185/03007991003648015.
^ ^5.0 ^5.1 Graf P. Rhinitis medicamentosa: aspects of pathophysiology and treatment. Allergy. 1997, 52 (40 Suppl): 28–34. PMID 9353558. S2CID 72326981. doi:10.1111/j.1398-9995.1997.tb04881.x.
^ Xylometazoline nasal medical facts from Drugs.com. www.drugs.com. [28 December 2016]. （原始內容存檔於29 December 2016）.

[UK2016-1] 1.0 ^1.1 ^1.2 Otrivine Adult Measured Dose Sinusitis Spray - Summary of Product Characteristics (SPC) - (eMC). www.medicines.org.uk. 13 April 2016 [28 December 2016]. （原始內容存檔於29 December 2016）.

[BNF69-2] 2.0 ^2.1 ^2.2 ^2.3 British national formulary : BNF 69 69. British Medical Association. 2015: 786. ISBN 9780857111562.

[WHO21st-3] World Health Organization. World Health Organization model list of essential medicines: 21st list 2019. Geneva: World Health Organization. 2019. hdl:10665/325771 . WHO/MVP/EMP/IAU/2019.06. License: CC BY-NC-SA 3.0 IGO.

[sideeff-4] 4.0 ^4.1 Eccles R, Martensson K, Chen SC. Effects of intranasal xylometazoline, alone or in combination with ipratropium, in patients with common cold. Current Medical Research and Opinion. April 2010, 26 (4): 889–899. PMID 20151787. S2CID 34728458. doi:10.1185/03007991003648015.

[Gra1997-5] 5.0 ^5.1 Graf P. Rhinitis medicamentosa: aspects of pathophysiology and treatment. Allergy. 1997, 52 (40 Suppl): 28–34. PMID 9353558. S2CID 72326981. doi:10.1111/j.1398-9995.1997.tb04881.x.

[MTM2016-6] Xylometazoline nasal medical facts from Drugs.com. www.drugs.com. [28 December 2016]. （原始內容存檔於29 December 2016）.

[1]

[2]

[3]

[4]

[5]

[6]